3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several reasons.
Many are highly innovative corporations that develop breakthrough medicines for rare and hard-to-treat diseases. Even when they target more common conditions, some biotechs have deep lineups that allow them to generate steady revenue and profits.
Since lifesaving medicines are hardly optional, these drugmakers tend to perform better than most, even when the economy is down. That's an important selling point many biotech companies can offer investors. With that as a backdrop, here are three biotech stocks that are worth holding for years to come: CRISPR Therapeutics (NASDAQ: CRSP), Regeneron Pharmaceuticals (NASDAQ: REGN), and Sanofi (NASDAQ: SNY).
Source Fool.com
Regeneron Pharmaceuticals Inc. Stock
With 47 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 1091 € shows a slightly positive potential of 1.77% compared to the current price of 1072.0 € for Regeneron Pharmaceuticals Inc..
